Blog
Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
Companies advance nucleoside-modified messenger RNA (modRNA) candidate BNT162b2, which encodes an optimized SARS-CoV-2 full-length spike glycoprotein, at a 30 µg dose level in a 2 dose
Gilead Sciences and Satcher Health Leadership Institute at Morehouse School of Medicine Partner to Study Racial Health Inequities Associated with COVID-19
— Funding from Gilead will support creation of data map to systematically address the impact of the disease on Black and minority communities — FOSTER
NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020
SHELTON, CT / ACCESSWIRE / July 21, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) a global leader in the development of highly effective antiviral therapies
Impressive Results From CytoDyn’s Phase 2 Covid-19 Trial
39% of Patients in Placebo Arm Had SAEs as Compared to Only 14% of Patients in Leronlimab Arm Had SAEs, Which Were Unrelated to Leronlimab.
COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial
Interim data showed strong antibody and T-cell responses Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
— Data Presented Includes a Comparative Analysis of Clinical Recovery and Mortality Outcomes from the Phase 3 SIMPLE Trial Versus Real-World Cohort of Severe COVID-19
Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program
Terminates AG013 Oral Mucositis Development Program TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or “the Company”) today provided an update on progress with its SARS-CoV-2
Medidata Partners With CTI for Remote Source Review of Clinical Trials in Response to COVID-19
Medidata, the global leader in creating end-to-end solutions to support the entire clinical trial process, and a Dassault Systèmes company, announced that CTI Clinical Trial
Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19
Approach stimulates immune response by activating B cells to enhance antibody production Safety and scientific basis supported by ongoing cancer clinical trial Study designed to
Regeneron Announces Manufacturing and Supply Agreement for BARDA and U.S. Department of Defense for REGN-COV2 Anti-Viral Antibody Cocktail
TARRYTOWN, N.Y., July 7, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.(NASDAQ: REGN) today announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), part
Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure
PARIS and CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) — Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of
Hoth Therapeutics Announces Sponsored Research Agreement with VCU for Potential COVID-19 Treatment
Hoth has exclusive license to this novel peptide COVID-19 therapeutic NEW YORK, June 30, 2020 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into